Conjunctivitis is an inflammation of the eye (also known as “pink eye”) which is often classified as either “Newborn” or “Childhood” conjunctivitis.
Childhood conjunctivitis is often caused by bacteria (Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumonia or Chlamydia trachomatis) though it also may result from a viral infection (e.g. adeno and herpes viruses), chemical exposure or allergies.
Pediatricians frequently prescribe topical antibiotics for childhood conjunctivitis though the evidence for their effectiveness is limited and conflicting.
A clinical trial of 88 children (aged 6 months – 7 years) with acute infective bacterial conjunctivitis, randomized to receive either moxifloxacin eye drops (a Quinolone), a placebo or no intervention, and followed for 14 days evaluated clinical outcomes (measured as the proportion of children with conjunctival symptoms on days 3-6).
Topical antibiotic therapy for acute infective conjunctivitis shortens time to clinical cure from 5.7 days (vs. no intervention) to 3.8 days (placebo eye drops and antibiotics having similar effects).
(A meta-analysis of 584 children with acute infective conjunctivitis treated with antibiotics or placebo indicates superiority of antibiotic eye drops over placebo).